FogChain Corp. (CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the " Company " or " FogChain "), announces that the Company intends to settle a total of $85,000 of debt (the " Debt ") owed to an administrative services provider of the Company, through the issuance of an aggregate of 1,545,454 common shares of the Company (the " Debt Shares ") at a deemed price of $0.055 per Debt Share (the " Debt Settlement ").

All the Debt Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance, in accordance with applicable securities legislation.

About FogChain Corp.

FogChain was previously seeking to be an end-to-end software development life cycle (SDLC) and quality assurance solutions provider, but the Company's business is now limited to identifying and evaluating assets or businesses for an acquisition.

Learn more at

Forward-Looking Information

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, "anticipates", "expects", "is expected", "intends", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. Forward-looking statements include those relating to the settlement of the Debt and the corresponding issuance of the Debt Shares. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, undue reliance should not be placed on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors, including, but not limited to, the equity markets generally, that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Except as required by law, FogChain undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Canadian Securities Exchange (" CSE ") nor its market regulator does not accept responsibility for the adequacy or accuracy of this news release. The CSE has in no way passed upon the merits of the proposed Debt Settlement and has neither approved nor disapproved the contents of this news release.

SOURCE FogChain Corp.

Cision View original content:

News Provided by Canada Newswire via QuoteMedia

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Abstracts represent exciting research progress across four cancers where patients have limited treatment options

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa Ph.D., "Astellas") will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Hybrid Congress from June 9-12 . A total of 13 abstracts from the company's expanding portfolio of approved and investigational therapies will be presented across both meetings, underscoring the company's commitment to advancing treatment options for advanced and rare cancers, including prostate, pancreatic and urothelial cancer, as well as acute myeloid leukemia (AML).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd. Buyout

Rigrodsky Law, P.A. is investigating Biohaven Pharmaceutical Holding Co. Ltd. ("Biohaven") (NYSE: BHVN) regarding possible breaches of fiduciary duties and other violations of law related to Biohaven's agreement to be acquired by Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Biohaven's shareholders will receive $148.50 in cash for each share of Biohaven common stock they own.

To learn more about this investigation and your rights, visit:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

BIOHAVEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. (NYSE: PFE).  Under the terms of the proposed transaction, shareholders of Biohaven will receive only $148.50 in cash and 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, for each share of Biohaven that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

KSF Filing Alert (PRNewsfoto/Kahn Swick & Foti, LLC)

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( ) toll free at any time at 855-768-1857, or visit to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit .

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision View original content to download multimedia:

SOURCE Kahn Swick & Foti, LLC

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven per Biohaven common share, a new publicly traded company that will retain Biohaven's non-calcitonin gene-related peptide development stage pipeline compounds.

(PRNewsfoto/WeissLaw LLP)

If you own Biohaven shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771

Weiss Law is investigating whether (i) Biohaven's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Biohaven's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at

Cision View original content to download multimedia:

SOURCE Weiss Law

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Pfizer, Inc. (NYSE: PFE).

Click here to learn more and participate in the action.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Pfizer to Acquire Biohaven Pharmaceuticals

Pfizer to commercialize NURTEC ® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need

Expands Pfizer's innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News